Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digitoxin in chronic heart failure with reduced ejection fraction
2013-005326-38Phase 4Completed
- Sponsor
- Hannover Medical School
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) comparing Digitoxin + standard of care with Placebo + standard of care (2 arms). Started Nov 2014; status: completed.
02
Drugs
digitoxin
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2013-005326-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005326-38.